Rabbit Monoclonal Antibodies
RevMAb Biosciences USA, Inc is a biotechnology company focused on the development of recombinant monoclonal antibodies using a revolutionary technology that does not require cell fusion and hybridoma generation. Our mission is to promote personal health by accelerating biomedical research and advancing disease diagnosis. We seek to accomplish this by providing superior monoclonal antibodies to our customers in the research and diagnostic fields.
RevMab are the first antibody company who developed this series of histone mutation antibodies. These antibodies have been extensively validated in human tissue samples by many epigenetics companies, research institutions, and pathology labs worldwide for years with more than 50 publications cited.
RevMAb Biosciences USA, Inc has developed a revolutionary monoclonal antibody generation method which allows development of monoclonal antibodies without generation of hybridoma. The recombinant antibodies are developed from a broad range of antigen-specific B cells that are inaccessible to traditional hybridoma technology. This revolutionary method has successfully been applied to develop high quality recombinant rabbit and goat monoclonal antibodies.
Instead of current hybridoma generation by cell fusion methods, we directly screen antibodies from immunized rabbit or goat B cells by immunoassays such as ELISA, Western Blot, etc. and identify desired B cells. We then clone cDNA and perform recombinant antibody production using transient and stable mammalian cell expression.
RevMAb offers a number of different rabbit and goat monoclonal antibody development and production services. We develop monoclonal antibodies directly from the isolated B Cells of immunized animals using our proprietary technology. The B cells are grown in 96-well plates and their supernatants are screened to identify the B cell clones that produce antigen specific antibodies for desired applications. The antibodies are recombinantly produced by cloning their H and L chain cDNAs and expressing them in mammalian cells. Our technology has so far been successfully applied to produce a various range of antibodies with high specificity and affinity for research, diagnostic, and therapeutic use. Please contact us for more information.